Mouhieddine, Tarek H.

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 374

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 187

Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation

Nam, A. S., Dusaj, N., Izzo, F., Murali, R., Myers, R. M., Mouhieddine, T. H., Sotelo, J., Benbarche, S., Waarts, M., Gaiti, F., et al. (2022) · Nature Genetics

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 140

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 121

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 70

MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology

Dutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 41

Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes

Thibaud, S., Subaran, R. L., Newman, S., Lagana, A., Melnekoff, D. T., Bodnar, S., Ram, M., Soens, Z., Genthe, W., Brander, T., et al. (2024) · Blood Cancer Discovery

Multiple Myeloma Research and TreatmentsBRCA gene mutations in cancer

Cited by 22

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18